SecBot SecBot
SECBOTREPLAY Home › Report › MGNX

MGNX · MacroGenics entered into a definitive agreement to sell its GMP…

MACROGENICS INC · 8-K filed May 12, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

8-K filed May 12, 2026 at 08:00 ET

MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO business) to Bora Pharmaceuticals for a $122.5 million upfront cash payment, subject to customary closing adjustments and up to $5 million in contingent milestones. The transaction, expected to close in Q3 2026, provides non-dilutive capital to fund the company's R&D pipeline while retaining manufacturing access via a supply agreement.

  • Base purchase price of $122.5 million in cash at closing, subject to working capital and indebtedness adjustments.
  • Up to $5 million in additional contingent payments based on manufacturing milestones through 2028.
  • Transaction includes transfer of the Rockville, MD manufacturing facility (11,000L capacity) and Frederick, MD warehouse.
  • Approximately 140 MacroGenics employees expected to be hired by Bora.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access